Drug for treating glaucoma

A glaucoma and drug technology, applied in the field of biochemistry and molecular biology, can solve the problem of rare research on distribution, and achieve the effect of reducing expression level and treating glaucoma

Active Publication Date: 2013-11-06
ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few studies on the application of RNA interference to directly reduce intraocular pressure in the eye to treat glaucoma and the distribution of siRNA after anterior chamber injection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for treating glaucoma
  • Drug for treating glaucoma
  • Drug for treating glaucoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1. RhoA siRNA design: According to existing literature reports and experimental experience, using biological software, according to the RhoA gene sequence published by GenBank, the sequence with the highest software score was designed and selected. Finally, the BLAST software provided by NCBI GenBank (written by the National Library of Medicine and the National Institutes of Health) was used to perform homology analysis on the selected target sequences to exclude the possibility that siRNA non-specifically inhibits other gene fragments in mice and humans. The company entrusted with designing and synthesizing the sequence is Guangzhou Ruibo Biological Co., Ltd.

[0023] RNA interference target sequence of RhoA: 5'-GAAGTCAAGCATTTCTGTC-3'

[0024] The nucleotide sequence of the RhoA siRNA (double strand) designed according to the RNA interference target sequence of RhoA: 5'-GAAGTCAAGCATTTCTGTC-3' is thus:

[0025] Sense strand: 5′GAAGUCAAGCAUUUCUGUC dTdT 3′,

[0026] The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a drug for treating glaucoma. According to the drug, a RNA interference sequence RhoA siRNA is adopted as an active ingredient, wherein a sense strand of the RhoA siRNA is 5'GAAGUCAAGCAUUUCUGUCdTdT3', an antisense strand is 3'dTdTCUUCAGUUCGUAAAGACAG5'. With the RhoA siRNA prepared according to a RNA interference target sequence 5'-GAAGTCAAGCATTTCTGTC-3' of the RhoA in the present invention, an expression level of RhoA mRNA can be effectively reduced, an expression level of RhoA protein in anterior chamber tissue can be efficiently down-regulated, stress fiber formation is affected so as to affect changes of cytoskeleton structures and distributions of actin of trabecular meshwork cells, such that trabecular meshwork cell channel configuration is changed, aqueous humor discharge resistance is changed, and intraocular pressure is affected so as to achieve a purpose of treatment of glaucoma.

Description

Technical field: [0001] The invention belongs to the field of biochemistry and molecular biology, and in particular relates to a medicine for treating glaucoma. Background technique: [0002] Glaucoma is currently the second irreversible blinding eye disease in the world. It is a group of eye diseases that cause optic nerve damage caused by elevated intraocular pressure or other factors, manifested as visual field damage, optic disc depression expansion, and retinal nerve fiber layer atrophy. The main risk factor for the occurrence and development of glaucoma is the presence of high intraocular pressure. [0003] The pathogenesis of glaucoma has not been fully elucidated. The pathological increase in intraocular pressure caused by the increase of aqueous humor outflow resistance in the trabecular meshwork is the main cause of primary open-angle glaucoma. The biological function and configuration of trabecular meshwork cells depend on the cytoskeleton composed of actin fiber...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61P27/06
Inventor 余敏斌刘茜吴开力
Owner ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap